SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-053612
Filing Date
2024-05-06
Accepted
2024-05-06 16:35:33
Documents
64
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dawn-20240331.htm   iXBRL 10-Q 1883612
2 EX-31.1 dawn-ex31_1.htm EX-31.1 13516
3 EX-31.2 dawn-ex31_2.htm EX-31.2 13338
4 EX-32.1 dawn-ex32_1.htm EX-32.1 7665
5 EX-32.2 dawn-ex32_2.htm EX-32.2 8566
6 GRAPHIC img13563450_0.jpg GRAPHIC 263092
  Complete submission text file 0000950170-24-053612.txt   8066712

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dawn-20240331.xsd EX-101.SCH 1407764
68 EXTRACTED XBRL INSTANCE DOCUMENT dawn-20240331_htm.xml XML 1051555
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005 650 484-0899
Day One Biopharmaceuticals, Inc. (Filer) CIK: 0001845337 (see all company filings)

IRS No.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40431 | Film No.: 24918123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)